Severe COVID-19 patients who received IVIG in the early phase of the disease did not show better clinical outcomes in terms of mortality, hospitalization time and intensive care unit admission compared to those who received tocilizumab.

In addition, there are no data to support the use of IVIG in COVID-19 treatment due to the higher incidence of serious side effects in IVIG recipients and the significantly higher cost of IVIG treatment compared to tocilizumab.

This study was designed retrospectively and included COVID-19 patients with severe but not critical disease who required low-flow oxygen support and received tocilizumab and/or IVIG treatments.

The researchers screened the hospital records of patients who were admitted to Zonguldak Atatürk State Hospital, Turkey, from July 5 to October 5, 2020 with a COVID-19 diagnosis and were followed up.

Read More